Genmab — Maj 2020

[Solsen]

Selvfølgelig. Men jeg tror det halve år JW har talt om var optimistisk.

[B.Andersen]

1.805

[JKY_VH]

så smuttede vi over på "den anden side":-)

[Plimsoller]

Mon hatten skal rundt Helge?

[Legolas23]

Stor partner deaal lurer. Jeg forstår godt dem som køber ????

[Solsen]

Hold da op har været i 1813,5

[Bulder]

Interessant oplysning fra the new kid on the block: they've amended all company-sponsored clinical studies of daratumumab to allow patients to switch from the IV formulation to the subcutaneous formulation if there is a patient and physician desire to do so.

[Solsen]

God oplysning Bulder.

[E_L]

who knows if the Roche CD3xCD20 is combined with chemotherapy in their trials?

[JohnW]

Er Genmab ikke blevet for store til at blive opkøbt? Nu er de vel blevet anderkendt som et udviklingsmæssigt "powerhouse", som JW ønskede?

[Legolas23]

@Bulder. Det må booste gennemstrømning og give plads til flere. Ketchup-effekt på patienter og kurs.

[GeorgeBest]

Jyske Bank raises target price on Genmab to 1825 from 1725

[Bulder]

E L I think mosunetuzumab is mono https://www.roche.com/investors/updates/inv-update-2019-12-07.htm

[E_L]

i think there are more trials. i am just wondering since Jan said "better treatment of CLL potentially in better and more efficacious regimes, which are without chemotherapy, so combinations of epcoritamab and potential small-molecule drugs, are of high, high interest to us and potential partners"

[Bulder]

Their CD20-TCB is combined with Gazyva

[E_L]

ok, thanks

[Solsen]

Saw RG6026 in the pipeline. Also a bispecific CD20/03 ?

[Helge_LarsenPI-redaktør]

Stil endelig spørgsmål i Q&A.

[E_L]

i think my 2 questions were probably already answered lol, up to you if you want to leave them in Helge

[E_L]

@Solsen yes, i think they got 2 https://www.fiercebiotech.com/biotech/ash-roche-bispecific-has-complete-responses-car-t-failures "Roche shared data on its other CD20xCD3 bispecific, code-named RG6026, at ASH."